Main > ONCOLOGY (**) > Breast Cancer>ER->HER2->PR-> > TREAT.: > USA. G. MAb-Drug Conjugate Inj.>

---

>for IV Use

USA. G. MAb-Drug Conjugate Inj.>'s subsections
(*) CN Approval Date: 2022. 06.10
(*) EU CE Mark Date: 2021. 11.23.
(*) SG Approval Date: 2022. 02.07.
(*) USA Approval Date: 2020. 04.22.
>METASTATIC>2 Prior Therapies
Company
Company Licensee Asia Pacific
Drug>Topoisomerase Inh.>Govitecan
MAb>Trop-2 MAb: SacituzuMAb
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 10
Patent>UpDate: 2022. 07.12.
TM
TM Web-Site

USA. G. MAb-Drug Conjugate Inj.>'s products
This section has no products